Senti Biosciences, Inc. (NASDAQ:SNTI) Given Average Recommendation of “Moderate Buy” by Analysts

Senti Biosciences, Inc. (NASDAQ:SNTI) has been assigned an average rating of “Moderate Buy” from the five research firms that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $9.00.

SNTI has been the subject of a number of research analyst reports. Chardan Capital raised their price target on shares of Senti Biosciences from $12.00 to $13.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. Weiss Ratings reissued a “sell (e+)” rating on shares of Senti Biosciences in a research report on Thursday, January 22nd. Wall Street Zen upgraded Senti Biosciences to a “sell” rating in a research note on Saturday, December 13th. Leerink Partners initiated coverage on Senti Biosciences in a research note on Friday, November 21st. They set an “outperform” rating and a $6.00 price target on the stock. Finally, HC Wainwright started coverage on Senti Biosciences in a report on Tuesday, October 14th. They issued a “buy” rating and a $12.00 price objective on the stock.

Senti Biosciences Price Performance

Shares of NASDAQ:SNTI opened at $0.98 on Wednesday. The business’s 50-day moving average is $1.32 and its 200 day moving average is $1.57. Senti Biosciences has a 1 year low of $0.95 and a 1 year high of $5.10. The firm has a market capitalization of $25.76 million, a P/E ratio of -0.29 and a beta of 2.13.

Senti Biosciences (NASDAQ:SNTI) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.10). On average, analysts expect that Senti Biosciences will post -14.54 EPS for the current year.

Institutional Trading of Senti Biosciences

Institutional investors and hedge funds have recently bought and sold shares of the business. Citadel Advisors LLC acquired a new stake in shares of Senti Biosciences in the third quarter worth $117,000. Geode Capital Management LLC lifted its position in Senti Biosciences by 395.6% during the second quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock valued at $311,000 after purchasing an additional 117,588 shares during the period. Finally, Armistice Capital LLC purchased a new stake in Senti Biosciences in the second quarter valued at $1,883,000. 25.70% of the stock is currently owned by institutional investors and hedge funds.

Senti Biosciences Company Profile

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.